KATHLEEN STUMP: Open Payments
NPI 1073068300 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,573 in 89 payments from 16 companies in 2025. Trend: 2023 $1,585 · 2024 $901 · 2025 $1,573
Food & beverage: $1,474Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $413 |
| Janssen Biotech, Inc. | 13 | $274 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $136 |
| Phathom Pharmaceuticals, Inc. | 9 | $134 |
| Ardelyx, Inc. | 7 | $131 |
| Madrigal Pharmaceuticals | 3 | $75 |
| Gilead Sciences, Inc. | 3 | $68 |
| Lilly USA, LLC | 4 | $61 |
| Intercept Pharmaceuticals, Inc. | 3 | $51 |
| Aimmune Therapeutics, Inc. | 3 | $50 |
Products named: TREMFYA, RINVOQ, VOQUEZNA, IBSRELA, XIFAXAN, LINZESS, REZDIFFRA, CREON.
Industry payments across KY — which companies pay providers there.
